France (FR)

The attitudes of medical students in Europe toward the clinical importance of histology (2017) Moxham BJ, Emmanouil-Nikoloussi E, Brenner E, Plaisant O, Brichova H, Kucera T, Pais D, et al. Journal article Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Age calibration of the Lower Ordovician Fezouata Lagerstätte (Morocco) (2017) Lefebvre B, Lehnert O, Gutiérrez-Marco JC, Martin ELO, Nowak H, Akodad M, El Hariri K, Servais T Journal article PREDICTION OF PROGRESSIVE SKIN THICKENING IN EARLY DIFFUSE SYSTEMIC SCLEROSIS USING THREE-MONTHLY SKIN SCORES FROM THE EUROPEAN SCLERODERMA OBSERVATIONAL STUDY (ESOS) (2017) Herrick A, Peytrignet S, Pan X, Hesselstrand R, Mouthon L, Brown E, Czirjak L, et al. Conference contribution OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE (2017) Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Koetter I, Hachulla E, et al. Conference contribution APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM (2017) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution DURABILITY OF APREMILAST RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: LONG-TERM (208-WEEK) RESULTS FROM THE PALACE 1 TRIAL (2017) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution Current Practice of Anticoagulation for Pediatric VAD Therapy - A Multi-Institutional European Survey of the EXCOR Pediatric Investigator Group (EEPIG) (2017) Miera O, Schmitt KR, Menon AK, Ersel S, Reiprich A, Akintuerk H, Thul J, et al. Conference contribution Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) (2017) Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, et al. Conference contribution Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies (2017) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution